Cargando…

Response kinetics of host and experimental solid tumour after adriamycin.

The effects of adriamycin (Adr) on the solid-tumour model, hepatoma 3924A, and on critical organs of the host, were determined at intervals after single injections of 60 mg/m2 of the agent. A reduced rate of tumour growth was evident 4 days after treatment, continued to Day 11, and then returned to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, H. A., Looney, W. B., Teja, K., Hobson, A. S., MacLeod, M. S.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1978
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009638/
https://www.ncbi.nlm.nih.gov/pubmed/209806
_version_ 1782136155824717824
author Hopkins, H. A.
Looney, W. B.
Teja, K.
Hobson, A. S.
MacLeod, M. S.
author_facet Hopkins, H. A.
Looney, W. B.
Teja, K.
Hobson, A. S.
MacLeod, M. S.
author_sort Hopkins, H. A.
collection PubMed
description The effects of adriamycin (Adr) on the solid-tumour model, hepatoma 3924A, and on critical organs of the host, were determined at intervals after single injections of 60 mg/m2 of the agent. A reduced rate of tumour growth was evident 4 days after treatment, continued to Day 11, and then returned to rates comparable to control values. On Day 11 tumour volumes of treated animals were 38% of control. During the period of reduced growth, 3H-TdR incorporation into tumour DNA and percentage labelled tumour cells were less than control values. DNA concentration in tumour was not affected by drug treatment, which differs from observations made in other studies employing 5-fluorouracil (FU). No evidence of significantly increased necrosis or fibrosis of the tumour was found after Adr. The Adr treatment caused loss of 60% of the tibial marrow by Day 4, as measured by total DNA content. Marrow DNA recovered to control levels between Days 7 and 11. Incorporation of 3H-TdR into heart DNA was reduced more than 40% during the first week after Adr treatment; enhanced incorporation was observed on Day 11, and control levels were attained by Day 17. No significant pathological evidence of cardiac toxicity was found 2-21 days after Adr but degeneration of myocardial cells and oedema was prominent at 14 weeks.
format Text
id pubmed-2009638
institution National Center for Biotechnology Information
language English
publishDate 1978
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20096382009-09-10 Response kinetics of host and experimental solid tumour after adriamycin. Hopkins, H. A. Looney, W. B. Teja, K. Hobson, A. S. MacLeod, M. S. Br J Cancer Research Article The effects of adriamycin (Adr) on the solid-tumour model, hepatoma 3924A, and on critical organs of the host, were determined at intervals after single injections of 60 mg/m2 of the agent. A reduced rate of tumour growth was evident 4 days after treatment, continued to Day 11, and then returned to rates comparable to control values. On Day 11 tumour volumes of treated animals were 38% of control. During the period of reduced growth, 3H-TdR incorporation into tumour DNA and percentage labelled tumour cells were less than control values. DNA concentration in tumour was not affected by drug treatment, which differs from observations made in other studies employing 5-fluorouracil (FU). No evidence of significantly increased necrosis or fibrosis of the tumour was found after Adr. The Adr treatment caused loss of 60% of the tibial marrow by Day 4, as measured by total DNA content. Marrow DNA recovered to control levels between Days 7 and 11. Incorporation of 3H-TdR into heart DNA was reduced more than 40% during the first week after Adr treatment; enhanced incorporation was observed on Day 11, and control levels were attained by Day 17. No significant pathological evidence of cardiac toxicity was found 2-21 days after Adr but degeneration of myocardial cells and oedema was prominent at 14 weeks. Nature Publishing Group 1978-06 /pmc/articles/PMC2009638/ /pubmed/209806 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Hopkins, H. A.
Looney, W. B.
Teja, K.
Hobson, A. S.
MacLeod, M. S.
Response kinetics of host and experimental solid tumour after adriamycin.
title Response kinetics of host and experimental solid tumour after adriamycin.
title_full Response kinetics of host and experimental solid tumour after adriamycin.
title_fullStr Response kinetics of host and experimental solid tumour after adriamycin.
title_full_unstemmed Response kinetics of host and experimental solid tumour after adriamycin.
title_short Response kinetics of host and experimental solid tumour after adriamycin.
title_sort response kinetics of host and experimental solid tumour after adriamycin.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009638/
https://www.ncbi.nlm.nih.gov/pubmed/209806
work_keys_str_mv AT hopkinsha responsekineticsofhostandexperimentalsolidtumourafteradriamycin
AT looneywb responsekineticsofhostandexperimentalsolidtumourafteradriamycin
AT tejak responsekineticsofhostandexperimentalsolidtumourafteradriamycin
AT hobsonas responsekineticsofhostandexperimentalsolidtumourafteradriamycin
AT macleodms responsekineticsofhostandexperimentalsolidtumourafteradriamycin